[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

FDA says GSK-Vir’s sotrovimab no longer authorized to treat COVID in U.S

04/05/2022

Less than a minute

2022.04.05 21:17

FDA says GSK-Vir's sotrovimab no longer authorized to treat COVID in U.S
FILE PHOTO: A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay

(Reuters) – The U.S. health regulator said on Tuesday GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology (NASDAQ:VIR)’s drug sotrovimab was no longer authorized to treat COVID-19 in the U.S. due to an increase in the proportion of cases caused by the Omicron BA.2 sub-variant.

Source

04/05/2022

Less than a minute